Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 5 of the 13 calendar months from Oct 2025 to Oct 2026: Oct 2025, Nov 2025, Dec 2025, Jan 2026 and Feb 2026.
- Largest single sale: $1.5M (50,000 shares) of Enliven Therapeutics, Inc. on Jan 9, 2026. Filing
- Last sale before this period: Sep 26, 2025.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | Chief Scientific Officer | Feb 27, 2023 | Feb 17, 2026 |
Recent filings
The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Feb 12, 2026, Enliven Therapeutics, Inc.: 18,750 shares granted. 1 filing: 1
- Feb 6, 2026, Enliven Therapeutics, Inc.: sold 5,000 shares for $145K, under a disclosed plan (some held indirectly). 1 filing: 1
- Jan 20, 2026, Enliven Therapeutics, Inc.: sold 20,000 shares for $535K, under a disclosed plan (some held indirectly). 1 filing: 1
- Jan 9, 2026, Enliven Therapeutics, Inc.: sold 91,198 shares for $2.5M, under a disclosed plan (some held indirectly). 1 filing: 1
- Jan 8, 2026, Enliven Therapeutics, Inc.: sold 41,302 shares for $993K, under a disclosed plan (some held indirectly). 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.